IDXG Stock — Interpace Biosciences Inc

Interpace Biosciences Inc (IDXG)

Updated October 16, 2026.

IDXG is a Stock. Its deepest 1-year drawdown was 35.1%.

Interpace Biosciences provides molecular diagnostic tests and pathology services focused on evaluating cancer risk, primarily through thyroid nodule assessment using proprietary testing platforms including ThyGeNEXT and ThyraMIR v2; it serves physicians, cancer centers, hospitals, and laboratory networks across the United States. The company does not currently distribute to shareholders. This security may appeal to investors seeking exposure to the diagnostics and cancer testing sector.

IDXG performance

Returns are updating. IDXG's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 35.1%.

IDXG key facts

Asset type

Stock

Asset class

Equity

Inception date

05/20/1998

Distribution frequency

None

Last close

$5.05 (as of 2026-10-16)

Market cap

$29,804,908

Average volume

102.0

Payment date

01/15/2020

Beta

0.628

Payout ratio

0.0%

P/E ratio

1.12

Forward P/E

7.1582

EPS

$4.50

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

IDXG risks and drawbacks

The deepest 1-year drawdown on record here is 35.1%.

Who may consider IDXG — and who may not

It is a weaker fit for investors who need monthly cash flow (IDXG does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on IDXG

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions